Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557735 · ClinicalTrials.gov registry record · Phase 3
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT04557735 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT04557735, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
Interventions
- DRUG Ravulizumab
- OTHER Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557735
The ClinicalTrials.gov registry entry for NCT04557735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ravulizumab is the first listed.
NCT04557735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04557735 about?
NCT04557735 is a clinical study titled "Study of Ravulizumab in Pediatric Participants With HSCT-TMA". This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up peri...
What is the current status of trial NCT04557735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2020-12-07. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT04557735?
The interventions under investigation include: Ravulizumab (DRUG), Best Supportive Care (OTHER).
Who is sponsoring clinical trial NCT04557735?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.